The same mRNA technology that revolutionized COVID-19 vaccines has just cleared a major hurdle for flu season. Moderna's experimental flu vaccine outperformed standard flu shots by 27% in a massive trial involving more than 40,000 adults across 11 countries.
The results, submitted to the FDA for approval, show what many researchers have hoped for since the pandemic: that mRNA's flexibility could finally give us better tools against influenza's shape-shifting nature.
In the trial, which ran during the 2024-2025 flu season, just 2% of people who received the mRNA vaccine got sick, compared to 2.8% in the standard vaccine group. Among adults 65 and older—the group most vulnerable to flu complications—the difference was even more pronounced: 1.9% versus 2.6%.
Now, before we declare victory over flu season: these aren't exactly blockbuster numbers in absolute terms. We're talking about reducing infection rates by less than one percentage point. But in the world of flu vaccines, where effectiveness varies wildly year to year (sometimes dipping as low as 10%), consistent improvement matters.
The real promise here is speed. Traditional flu vaccines are grown in chicken eggs, a process that takes months and locks in your best guess about which flu strains will circulate six months later. mRNA vaccines can be designed and manufactured in weeks, potentially allowing better matching to emerging strains.
Dr. Jesse Goodman, an infectious disease specialist at Georgetown University, emphasized this advantage: "The ability to make vaccine in shorter time periods may help better match new vaccines to emerging viruses."
The side effects were predictable: fatigue, headache, and arm pain, slightly more common than with traditional shots but mild and short-lived. Anyone who's had an mRNA COVID vaccine knows the drill.
The FDA is expected to decide by August 5, 2026. The application is split into two tracks: standard approval for adults 50-64 and accelerated approval for those 65 and older, who face the highest risk from flu.
Dorit Reiss, a vaccine policy expert, called the results "strong" and suggested the FDA would likely approve. But here's the catch: even if approved this summer, widespread availability for the 2026-2027 flu season depends on manufacturing scale-up and distribution logistics.
